These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

278 related items for PubMed ID: 25862597

  • 21. Delamanid in the treatment of multidrug-resistant tuberculosis.
    Gupta R, Wells CD, Hittel N, Hafkin J, Geiter LJ.
    Int J Tuberc Lung Dis; 2016 Dec 01; 20(12):33-37. PubMed ID: 28240570
    [Abstract] [Full Text] [Related]

  • 22. Interim outcomes of delamanid for the treatment of MDR- and XDR-TB in South Korea.
    Mok J, Kang H, Hwang SH, Park JS, Kang B, Lee T, Koh WJ, Yim JJ, Jeon D.
    J Antimicrob Chemother; 2018 Feb 01; 73(2):503-508. PubMed ID: 29069496
    [Abstract] [Full Text] [Related]

  • 23. Cost comparison of nine-month treatment regimens with 20-month standardized care for the treatment of rifampicin-resistant/multi-drug resistant tuberculosis in Nigeria.
    Bada FO, Blok N, Okpokoro E, Dutt S, Akolo C, Dakum P, Abimiku A.
    PLoS One; 2020 Feb 01; 15(12):e0241065. PubMed ID: 33259492
    [Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25. Bedaquiline and delamanid for the treatment of multidrug-resistant tuberculosis: a multicentre cohort study in Korea.
    Kim CT, Kim TO, Shin HJ, Ko YC, Hun Choe Y, Kim HR, Kwon YS.
    Eur Respir J; 2018 Mar 01; 51(3):. PubMed ID: 29545276
    [Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. Cost-effectiveness of adding rh-endostatin to first-line chemotherapy in patients with advanced non-small-cell lung cancer in China.
    Wu B, Chen H, Shen J, Ye M.
    Clin Ther; 2011 Oct 01; 33(10):1446-55. PubMed ID: 21992806
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. Clinical benefit of delamanid (OPC-67683) in the treatment of multidrug-resistant tuberculosis patients in China.
    Zhang Q, Liu Y, Tang S, Sha W, Xiao H.
    Cell Biochem Biophys; 2013 Oct 01; 67(3):957-63. PubMed ID: 23546935
    [Abstract] [Full Text] [Related]

  • 33. Cost-utility analysis of high-dose treatment for intermediate-susceptible, dose-dependent tuberculosis patients.
    Zuur MA, van Asselt ADI, van 't Boveneind-Vrubleuskaya N, Aleksa A, Postma MJ, Alffenaar JWC.
    Int J Tuberc Lung Dis; 2018 Sep 01; 22(9):991-999. PubMed ID: 30092863
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. Modelling cost effectiveness and cost utility of sequential DMARD therapy including leflunomide for rheumatoid arthritis in Germany: II. The contribution of leflunomide to efficiency.
    Schädlich PK, Zeidler H, Zink A, Gromnica-Ihle E, Schneider M, Straub C, Brecht JG, Huppertz E.
    Pharmacoeconomics; 2005 Sep 01; 23(4):395-420. PubMed ID: 15853438
    [Abstract] [Full Text] [Related]

  • 36. Feasibility and cost-effectiveness of standardised second-line drug treatment for chronic tuberculosis patients: a national cohort study in Peru.
    Suárez PG, Floyd K, Portocarrero J, Alarcón E, Rapiti E, Ramos G, Bonilla C, Sabogal I, Aranda I, Dye C, Raviglione M, Espinal MA.
    Lancet; 2002 Jun 08; 359(9322):1980-9. PubMed ID: 12076553
    [Abstract] [Full Text] [Related]

  • 37. Delamanid: a review of its use in patients with multidrug-resistant tuberculosis.
    Blair HA, Scott LJ.
    Drugs; 2015 Jan 08; 75(1):91-100. PubMed ID: 25404020
    [Abstract] [Full Text] [Related]

  • 38. Levofloxacin versus placebo for the prevention of tuberculosis disease in child contacts of multidrug-resistant tuberculosis: study protocol for a phase III cluster randomised controlled trial (TB-CHAMP).
    Seddon JA, Garcia-Prats AJ, Purchase SE, Osman M, Demers AM, Hoddinott G, Crook AM, Owen-Powell E, Thomason MJ, Turkova A, Gibb DM, Fairlie L, Martinson N, Schaaf HS, Hesseling AC.
    Trials; 2018 Dec 20; 19(1):693. PubMed ID: 30572905
    [Abstract] [Full Text] [Related]

  • 39. Tuberculosis: cost of illness in Germany.
    Diel R, Rutz S, Castell S, Schaberg T.
    Eur Respir J; 2012 Jul 20; 40(1):143-51. PubMed ID: 22267754
    [Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 14.